GlassScriptPhysician profile
Anne Amberg
NPI 1538257779
$5,677.96
in general payments reported to CMS, 2019-2025
30 companies · $995 in 2025
The $995 reported for 2025 was more than what 84% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,435 · 2022: $442 · 2023: $719 · 2024: $1,087 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,800.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,073.20 | 2021-2025 | |
| Corcept Therapeutics | $569.27 | 2021-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $549.79 | 2021-2025 | Airsupra, Tezspire |
| Novo Nordisk INC | $484.26 | 2021-2025 | Ozempic |
| Amgen INC. | $292.51 | 2021-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.42 | 2021-2023 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $288.11 | 2021-2024 | Rexulti, Jynarque |
| Lilly USA, LLC | $272.05 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $234.32 | 2021-2023 | |
| Actelion Pharmaceuticals US, INC. | $230.95 | 2024-2025 | Opsumit, Uptravi |
| Teva Pharmaceuticals USA, INC. | $174.54 | 2023-2025 | Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $125.00 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.97 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $123.53 | 2025 | |
| Genzyme Corporation | $120.24 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $89.91 | 2025 | Ibsrela |
| Gilead Sciences, INC. | $79.00 | 2021 | |
| Astellas Pharma US INC | $76.68 | 2021 | |
| Endo Pharmaceuticals INC. | $71.43 | 2021 | |
| Phathom Pharmaceuticals, INC. | $68.68 | 2024 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $67.82 | 2021 | |
| Amarin Pharma, INC. | $65.30 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.19 | 2021 | |
| Eisai INC. | $35.00 | 2021 | |
| Merck Sharp & Dohme LLC | $25.24 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.79 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $23.63 | 2021 | |
| Genentech USA, INC. | $23.33 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.20 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Amberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.